Inspiratory Effort and Respiratory Mechanics in Spontaneously Breathing Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Matched Control Study
IERATIC
1 other identifier
observational
20
0 countries
N/A
Brief Summary
Idiopathic pulmonary fibrosis is a life-threatening lung disease characterized by progressive deterioration of lung function and a median survival time of 3-5 years from diagnosis. The onset of an acute deterioration (AE) of respiratory function, the so called acute exacerbation of IPF (AE-IPF), may lead to severe hypoxemia, further worsening prognosis. During these events, the typical usual interstitial pneumonia pattern (UIP) - the radiologic and histologic hallmark of IPF- is overlapped with diffuse alveolar damage (DAD), sharing similarities with the acute respiratory distress syndrome (ARDS) and often requiring respiratory assistance. Several studies show that the need for mechanical ventilation (MV) is associated with high mortality in IPF patients, probably due to the pathophysiological properties of UIP-like fibrotic lung (i.e. collapse induration areas, elevated lung elastance, high inhomogeneity) that make it more susceptible to ventilatory-induced lung injury (VILI). It has been theorized that the application of PEEP on a UIP-like lung pattern can determine the protrusion of the most distensible areas through a dense anelastic fibrotic tissue circles, causing increased rigidity, worsening compliance, and thus enabling tissue breakdown. In this scenario, non-invasive mechanical ventilation (NIV) may therefore represent an alternative option to assist these patients, although no specific recommendations have been made so far. In patients with ARDS, the efficacy of NIV in reducing the patient's inspiratory effort early after its application has been related to a favorable clinical outcome. Indeed, the mitigation of respiratory drive might have resulted in a lower risk for the self-inflicted lung injury (SILI) during spontaneous breathing, whose onset is very likely to worse outcomes of patients undergoing acute respiratory failure (ARF). To date no data available on the inspiratory effort and the lung mechanics in patients with AE-IPF either during unassisted of assisted spontaneous breathing. Aim of this study was then to compare respiratory mechanics, at baseline and 2-h following NIV application, in AE-IPF and ARDS patients matched for severity.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Aug 2016
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2016
CompletedFirst Submitted
Initial submission to the registry
March 28, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2022
CompletedFirst Posted
Study publicly available on registry
April 6, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2026
ExpectedApril 25, 2025
April 1, 2025
5.7 years
March 28, 2022
April 24, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Inspiratory effort in IPF patients
Assessment of esophageal pressure swing in IPF patients during acute exacerbation of disease as compared to ARDS
On respiratory intensive care unit admission
Secondary Outcomes (1)
Respiratory mechanics change after NIV application in IPF patients acute exacerbation
2 hours
Study Arms (2)
IPF patients with UIP pattern requiring NIV
ARDS patients requiring NIV
Eligibility Criteria
Patients with IPF developing AE consecutively admitted to the Respiratory Intensive Care Unit and the Intensive Care Unit of the University Hospital of Modena over the period August 1st, 2016 to January 1th, 2022 were prospectively considered eligible for enrollment.
You may qualify if:
- previously established diagnosis of IPF; occurring acute exacerbation of IPF as defined by an acute, clinically significant respiratory deterioration characterized by evidence of new widespread alveolar abnormality on chest CT scan (12); age \>18 years; presence of ARF with PaO2/FiO2 ratio \<200 mmHg despite HFNC (set with at least 60 L/min and FiO2 higher than 0.6); suitability for a NIV trial according to the attending staff; consent to measure esophageal pressure.
You may not qualify if:
- acute cardiogenic pulmonary edema,
- concomitant hypercapnic respiratory failure (PaCO2 \>45 mmHg) of any etiology,
- neuromuscular disease or chest wall deformities,
- home long-term oxygen therapy,
- intolerance or contraindication to NIV, such as the need for immediate endotracheal intubation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Roberto Tonellilead
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Principal investigator
Study Record Dates
First Submitted
March 28, 2022
First Posted
April 6, 2022
Study Start
August 1, 2016
Primary Completion
April 1, 2022
Study Completion (Estimated)
August 1, 2026
Last Updated
April 25, 2025
Record last verified: 2025-04